Anlotinib plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: A prospective, single-arm, single-center, phase II clinical study.
15 auth. Xi Chen, Shuqun Zhang, Xuexin Li, Yinbin Zhang, Youhuai Li, Huafeng Kang, Guan Hai-tao, Qi She, Xiao-bin Ma, Y. Diao, ... Di Liu, W. Min, Mengjie Liu, Fei Wu, Cong Feng